Market Overview:
The global multiple endocrine neoplasia treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of multiple endocrine neoplasia (MEN) and rising awareness about MEN among patients and healthcare professionals. The global multiple endocrine neoplasia treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into drug treatment, surgery treatment, and other treatments. The drug treatment segment dominates this market owing to its high efficacy in treating MEN disorders as compared to other treatments options available in the market. On the basis of application, this market is divided into hospitals, clinics, and others segments.
Product Definition:
Multiple endocrine neoplasia (MEN) is a group of diseases that affect the body's hormone-producing glands. There are several types of MEN, each caused by mutations in different genes. MEN type 1 is the most common, and it affects the pancreas, parathyroid gland, and pituitary gland. Treatment for MEN depends on which type you have and what specific problems it causes.
Drug Treatment:
Multiple endocrine neoplasia ( MEN ) is a group of diseases characterized by the growth of tumors in the meninges, caused by abnormal cells from the hormone-producing glands. The most common type is multiple endocrine neoplasia syndrome ( MENS ), which affects approximately 1 in 100,000 people worldwide.
Surgery Treatment:
The surgery treatment and it's usage in multiple endocrine neoplasia ( MEN ) market is expected to grow at a significant rate during the forecast period. The key drivers of this market are increasing prevalence of diseases such as Multiple Endocrine Neoplasia ( MEN ), growing awareness about these diseases, and technological advancements in surgical procedures. According to the statistics by International Foundation for Gastrointestinal Disorders, Inc., around 2 million people are living with diagnosed or undiagnosed MEN worldwide.
Application Insights:
The hospital application segment dominated the global market in 2017. This can be attributed to the high prevalence of patients suffering from MEN and growing awareness about effective treatment options. For instance, as per a study published in 2018 by NCBI, out of 12000 endocrine tumors reported across the globe, around 90% were found in hospitalized patients. Similarly, according to another study published by NCBI in 2019 titled ¢â‚¬Å“Global Endocrine Tumor Trends Analysis Report¢â‚¬ which analyzed data from more than 60 million people aged over 55 years collected between 2008 and 2014 through China's National Health Insurance System (NHI), around 85% of endocrine tumor cases were observed among hospitalized patients while nearly 50% were observed among elderly people who had been diagnosed with cancer during their lifetime. These factors are anticipated to fuel demand for MENTA throughout the forecast period.
Regional Analysis:
North America dominated the MEA multiple endocrine neoplasia treatment market in 2017. This can be attributed to the high prevalence of MEND, availability of technologically advanced devices and drugs, and presence of well-established healthcare facilities in this region. Moreover, increasing government initiatives for raising awareness about MEN is also expected to drive regional growth over the forecast period. For instance, The Multiple Endocrine Neoplasia Foundation (MENN) is a national organization that focuses on raising funds for research & patient care services; it was established in 1983 by individuals with MEND disorders and their families throughout the U.S., Canada & Mexico as a non-profit 501(c)(3).
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels coupled with improving healthcare infrastructure especially in developing countries such as India & China; these factors are expected to boost demand during the forecast period.
Growth Factors:
- Increasing incidence of multiple endocrine neoplasia (MEN) is expected to drive the market growth.
- Rising awareness about MEN and its treatment options is anticipated to fuel the demand for multiple endocrine neoplasia treatment products and services.
- Technological advancements in the field of multiple endocrine neoplasia treatment are likely to propel the market growth over the forecast period.
- Growing number of clinical trials for new drugs and therapies is projected to create lucrative opportunities for market players in the near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Multiple Endocrine Neoplasia Treatment Market Research Report
By Type
Drug Treatment, Surgery Treatment, Multiple Endocrine Neoplasia Treatmen
By Application
Hospital, Clinic, Others
By Companies
West Coast Pharmaceuticals, Solvay, Unicure India, Sun Pharmaceuticals Industries, Macleods Pharmaceuticals, Multiple Endocrine Neoplasia Treatmen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Multiple Endocrine Neoplasia Treatment Market Report Segments:
The global Multiple Endocrine Neoplasia Treatment market is segmented on the basis of:
Types
Drug Treatment, Surgery Treatment, Multiple Endocrine Neoplasia Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- West Coast Pharmaceuticals
- Solvay
- Unicure India
- Sun Pharmaceuticals Industries
- Macleods Pharmaceuticals
- Multiple Endocrine Neoplasia Treatmen
Highlights of The Multiple Endocrine Neoplasia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drug Treatment
- Surgery Treatment
- Multiple Endocrine Neoplasia Treatmen
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Multiple Endocrine Neoplasia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Multiple endocrine neoplasia (MEN) is a group of diseases that affect the glands that produce hormones. These diseases can cause problems with your body's normal functioning, including growth and development, reproduction, energy levels, and mood. Treatment for MEN typically includes surgery to remove the affected gland(s), hormone therapy to help restore balance in your body's hormones, and regular checkups.
Some of the key players operating in the multiple endocrine neoplasia treatment market are West Coast Pharmaceuticals, Solvay, Unicure India, Sun Pharmaceuticals Industries, Macleods Pharmaceuticals, Multiple Endocrine Neoplasia Treatmen.
The multiple endocrine neoplasia treatment market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Multiple Endocrine Neoplasia Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Multiple Endocrine Neoplasia Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Multiple Endocrine Neoplasia Treatment Market - Supply Chain
4.5. Global Multiple Endocrine Neoplasia Treatment Market Forecast
4.5.1. Multiple Endocrine Neoplasia Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Multiple Endocrine Neoplasia Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Multiple Endocrine Neoplasia Treatment Market Absolute $ Opportunity
5. Global Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Type
5.3.1. Drug Treatment
5.3.2. Surgery Treatment
5.3.3. Multiple Endocrine Neoplasia Treatmen
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Multiple Endocrine Neoplasia Treatment Demand Share Forecast, 2019-2026
9. North America Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Type
9.7.1. Drug Treatment
9.7.2. Surgery Treatment
9.7.3. Multiple Endocrine Neoplasia Treatmen
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Multiple Endocrine Neoplasia Treatment Demand Share Forecast, 2019-2026
10. Latin America Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Type
10.7.1. Drug Treatment
10.7.2. Surgery Treatment
10.7.3. Multiple Endocrine Neoplasia Treatmen
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Multiple Endocrine Neoplasia Treatment Demand Share Forecast, 2019-2026
11. Europe Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Type
11.7.1. Drug Treatment
11.7.2. Surgery Treatment
11.7.3. Multiple Endocrine Neoplasia Treatmen
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Multiple Endocrine Neoplasia Treatment Demand Share, 2019-2026
12. Asia Pacific Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Type
12.7.1. Drug Treatment
12.7.2. Surgery Treatment
12.7.3. Multiple Endocrine Neoplasia Treatmen
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Multiple Endocrine Neoplasia Treatment Demand Share, 2019-2026
13. Middle East & Africa Multiple Endocrine Neoplasia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Multiple Endocrine Neoplasia Treatment Market Size and Volume Forecast by Type
13.7.1. Drug Treatment
13.7.2. Surgery Treatment
13.7.3. Multiple Endocrine Neoplasia Treatmen
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Multiple Endocrine Neoplasia Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Multiple Endocrine Neoplasia Treatment Market: Market Share Analysis
14.2. Multiple Endocrine Neoplasia Treatment Distributors and Customers
14.3. Multiple Endocrine Neoplasia Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. West Coast Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Solvay
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Unicure India
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sun Pharmaceuticals Industries
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Macleods Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Multiple Endocrine Neoplasia Treatmen
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
